Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21798240 | 0.77 | — | — | |
| SCHEMBL23675642 | 0.72 | HCRTR2 (0.36) | — | |
| SCHEMBL21798133 | 0.71 | — | — | |
| SCHEMBL21798404 | 0.68 | CYP3A4 (0.34) | LMNA | |
| SCHEMBL30772882 | 0.67 | — | — | |
| SCHEMBL27779031 | 0.65 | — | — | |
| SCHEMBL21798356 | 0.62 | — | — | |
| SCHEMBL29052929 | 0.62 | ALOX15 (0.41) | LMNAHSD17B10ALOX15CTNNB1 | |
| SCHEMBL114677 | 0.61 | — | — | |
| SCHEMBL25348447 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230052629-A1 | ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-02-16 | — | — | US | disclosed |
| US-11072610-B2 | Antiviral pyridopyrazinedione compounds | NOVARTIS AG (CH) | 2021-07-27 | — | — | US | disclosed |
| EP-3849979-A1 | ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS | Novartis AG (CH) | 2021-07-21 | — | — | EP | disclosed |
| WO-2020053654-A1 | ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS | NOVARTIS AG (CH) | 2020-03-19 | — | — | WO | disclosed |
| US-20200079772-A1 | ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS | NOVARTIS AG (CH) | 2020-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230052629-A1 | ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS | ZC3HAV1, IL5, TYMP | LMNA 2847/4885HSD17B10 1400/4885NAMPT 914/4885 |
| US-11072610-B2 | Antiviral pyridopyrazinedione compounds | ZC3HAV1, IL5, TYMP | LMNA 2847/4885HSD17B10 1400/4885NAMPT 914/4885 |
| US-20200079772-A1 | ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS | ZC3HAV1, IL5, TYMP | LMNA 2847/4885HSD17B10 1400/4885NAMPT 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.